Innovative Medicine worldwide operational sales grew 6.3%. Growth was driven by DARZALEX (daratumumab), ERLEADA (apalutamide), Other Oncology, and CARVYKTI (ciltacabtagene autoleucel) in Oncology, TREMFYA (guselkumab) in Immunology, SPRAVATO (esketamine) in Neuroscience, and OPSUMIT (macitentan) in Pulmonary Hypertension. Growth was partially offset by STELARA (ustekinumab) and SIMPONI/SIMPONI ARIA (golimumab) in Immunology. MedTech worldwide operational sales grew 6.4%, with net acquisitions and divestitures positively impacting growth by 2.7%. Operational sales growth was driven primarily by electrophysiology products and Abiomed in Cardiovascular, previously referred to as Interventional Solutions, contact lenses in Vision and wound closure products in General Surgery. Growth was partially offset by endocutter products in Advanced Surgery.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Notable companies reporting before tomorrow’s open
- Eli Lilly’s (NYSE:LLY) Crohn’s Disease Drug Outperforms JNJ’s Version
- Options Volatility and Implied Earnings Moves This Week, October 15 – October 18, 2024
- Johnson & Johnson (JNJ) Q3 Pre-Earnings: Here’s What to Expect
- Johnson & Johnson (JNJ) Q3 Earnings Cheat Sheet
Questions or Comments about the article? Write to editor@tipranks.com